EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 485 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Is a Genomic Test Better at Finding Aggressive Prostate Cancer? October 13, 2022 Trastuzumab Deruxtecan Demonstrates Durable Responses in Patients with Previously Treated HER2-mutated... September 27, 2023 FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory... March 18, 2021 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Load more HOT NEWS Opportunity and mentorship: Our new PhD programme aiming to open-up academia... March is Multiple Myeloma Action Month Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast
